Age: 81.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site pruritus, Vaccination site swelling
Clinical narrative: injection site redness, swelling, itch; injection site redness, swelling, itch; injection site redness, swelling, itch; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (injection site redness, swelling, itch), VACCINATION SITE SWELLING (injection site redness, swelling, itch) and VACCINATION SITE PRURITUS (injection site redness, swelling, itch) in an 81-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022M20A) for COVID-19 vaccination.     No Medical History Information was reported.  Concomitant products included VENLAFAXINE HYDROCHLORIDE (EFFEXOR), CLONAZEPAM (CLONAPIN) and MULTIVITAMIN [VITAMINS NOS] for an unknown indication.   On 26-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Feb-2021, the patient experienced VACCINATION SITE ERYTHEMA (injection site redness, swelling, itch), VACCINATION SITE SWELLING (injection site redness, swelling, itch) and VACCINATION SITE PRURITUS (injection site redness, swelling, itch). At the time of the report, VACCINATION SITE ERYTHEMA (injection site redness, swelling, itch), VACCINATION SITE SWELLING (injection site redness, swelling, itch) and VACCINATION SITE PRURITUS (injection site redness, swelling, itch) outcome was unknown.            No treatment information was provided. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 04-Mar-2021 and was forwarded to Moderna on 05-Mar-2021.    This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (injection site redness, swelling, itch), VACCINATION SITE SWELLING (injection site redness, swelling, itch) and VACCINATION SITE PRURITUS (injection site redness, swelling, itch) in an 81-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022M20A) for COVID-19 vaccination.     No Medical History Information was reported.  Concomitant products included VENLAFAXINE HYDROCHLORIDE (EFFEXOR), CLONAZEPAM (CLONAPIN) and MULTIVITAMIN [VITAMINS NOS] for an unknown indication.   On 26-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Feb-2021, the patient experienced VACCINATION SITE ERYTHEMA (injection site redness, swelling, itch), VACCINATION SITE SWELLING (injection site redness, swelling, itch) and VACCINATION SITE PRURITUS (injection site redness, swelling, itch). At the time of the report, VACCINATION SITE ERYTHEMA (injection site redness, swelling, itch), VACCINATION SITE SWELLING (injection site redness, swelling, itch) and VACCINATION SITE PRURITUS (injection site redness, swelling, itch) outcome was unknown.            No treatment information was provided.